Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases.
Biomarkers
CCL4
Cerebrospinal fluid
MCP-1
Neuroinflammation
Normal pressure hydrocephalus
PD-L1
Proteomics
Journal
Fluids and barriers of the CNS
ISSN: 2045-8118
Titre abrégé: Fluids Barriers CNS
Pays: England
ID NLM: 101553157
Informations de publication
Date de publication:
13 Oct 2023
13 Oct 2023
Historique:
received:
09
07
2023
accepted:
03
10
2023
medline:
2
11
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Neuroinflammatory processes have been suggested to play a role in the pathophysiology of neurodegenerative diseases and post-hemorrhagic hydrocephalus, but have rarely been investigated in patients with idiopathic normal pressure hydrocephalus (iNPH). The aim of this study was to investigate whether levels of inflammatory proteins in CSF are different in iNPH compared to healthy controls and patients with selected neurodegenerative disorders, and whether any of these markers can aid in the differential diagnosis of iNPH. Lumbar CSF was collected from 172 patients from a single center and represented iNPH (n = 74), Alzheimer's disease (AD) (n = 21), mild cognitive impairment (MCI) due to AD (n = 21), stable MCI (n = 22), frontotemporal dementia (n = 13), and healthy controls (HC) (n = 21). Levels of 92 inflammatory proteins were analyzed using a proximity extension assay. As a first step, differences between iNPH and HC were investigated, and proteins that differed between iNPH and HC were then compared with those from the other groups. The linear regressions were adjusted for age, sex, and plate number. Three proteins showed higher (MCP-1, p = 0.0013; CCL4, p = 0.0008; CCL11, p = 0.0022) and one lower (PD-L1, p = 0.0051) levels in patients with iNPH compared to HC. MCP-1 was then found to be higher in iNPH than in all other groups. CCL4 was higher in iNPH than in all other groups, except in MCI due to AD. PD-L1 was lower in iNPH compared to all other groups, except in stable MCI. Levels of CCL11 did not differ between iNPH and the differential diagnoses. In a model based on the four proteins mentioned above, the mean area under the receiver operating characteristic curve used to discriminate between iNPH and the other disorders was 0.91. The inflammatory cytokines MCP-1 and CCL4 are present at higher-and PD-L1 at lower-levels in iNPH than in the other investigated diagnoses. These three selected cytokines may have diagnostic potential in the work-up of patients with iNPH.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroinflammatory processes have been suggested to play a role in the pathophysiology of neurodegenerative diseases and post-hemorrhagic hydrocephalus, but have rarely been investigated in patients with idiopathic normal pressure hydrocephalus (iNPH). The aim of this study was to investigate whether levels of inflammatory proteins in CSF are different in iNPH compared to healthy controls and patients with selected neurodegenerative disorders, and whether any of these markers can aid in the differential diagnosis of iNPH.
METHODS
METHODS
Lumbar CSF was collected from 172 patients from a single center and represented iNPH (n = 74), Alzheimer's disease (AD) (n = 21), mild cognitive impairment (MCI) due to AD (n = 21), stable MCI (n = 22), frontotemporal dementia (n = 13), and healthy controls (HC) (n = 21). Levels of 92 inflammatory proteins were analyzed using a proximity extension assay. As a first step, differences between iNPH and HC were investigated, and proteins that differed between iNPH and HC were then compared with those from the other groups. The linear regressions were adjusted for age, sex, and plate number.
RESULTS
RESULTS
Three proteins showed higher (MCP-1, p = 0.0013; CCL4, p = 0.0008; CCL11, p = 0.0022) and one lower (PD-L1, p = 0.0051) levels in patients with iNPH compared to HC. MCP-1 was then found to be higher in iNPH than in all other groups. CCL4 was higher in iNPH than in all other groups, except in MCI due to AD. PD-L1 was lower in iNPH compared to all other groups, except in stable MCI. Levels of CCL11 did not differ between iNPH and the differential diagnoses. In a model based on the four proteins mentioned above, the mean area under the receiver operating characteristic curve used to discriminate between iNPH and the other disorders was 0.91.
CONCLUSIONS
CONCLUSIONS
The inflammatory cytokines MCP-1 and CCL4 are present at higher-and PD-L1 at lower-levels in iNPH than in the other investigated diagnoses. These three selected cytokines may have diagnostic potential in the work-up of patients with iNPH.
Identifiants
pubmed: 37833765
doi: 10.1186/s12987-023-00472-x
pii: 10.1186/s12987-023-00472-x
pmc: PMC10571396
doi:
Substances chimiques
Amyloid beta-Peptides
0
tau Proteins
0
Cytokines
0
B7-H1 Antigen
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Subventions
Organisme : Vetenskapsrådet
ID : 2021-02189
Organisme : Svenska Sällskapet för Medicinsk Forskning
ID : SG-22-0192
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Cancer Immunol Immunother. 2017 Jul;66(7):877-890
pubmed: 28349165
Fluids Barriers CNS. 2020 May 6;17(1):35
pubmed: 32375819
Fluids Barriers CNS. 2022 Mar 22;19(1):26
pubmed: 35317823
Cytokine. 2012 Oct;60(1):1-12
pubmed: 22766373
Int J Biochem Cell Biol. 2004 Oct;36(10):1882-6
pubmed: 15203102
Zhonghua Jie He He Hu Xi Za Zhi. 2012 Feb;35(2):102-6
pubmed: 22455965
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Neuroinflammation. 2018 Sep 24;15(1):276
pubmed: 30249283
J Clin Invest. 1999 Jun;103(12):1719-27
pubmed: 10377178
J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1117-1123
pubmed: 31167811
PLoS One. 2017 Sep 26;12(9):e0185541
pubmed: 28950005
Fluids Barriers CNS. 2022 Aug 10;19(1):62
pubmed: 35948938
Eur J Neurol. 2021 Apr;28(4):1153-1159
pubmed: 33316127
J Neuroimmunol. 1994 Feb;50(1):101-7
pubmed: 8300851
CNS Neurosci Ther. 2020 Dec;26(12):1230-1240
pubmed: 33242372
Acta Neurol Scand. 2007 Nov;116(5):333-9
pubmed: 17922727
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
J Cereb Blood Flow Metab. 2010 Apr;30(4):769-82
pubmed: 20029451
Neuro Endocrinol Lett. 2014;35(7):586-93
pubmed: 25617881
Kidney Int. 1992 Jul;42(1):95-101
pubmed: 1386129
Cell Adh Migr. 2012 Sep-Oct;6(5):390-6
pubmed: 22902764
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Curr Pharm Des. 2014;20(28):4580-8
pubmed: 24862889
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):778-81
pubmed: 10811706
Blood. 2003 Jan 1;101(1):210-5
pubmed: 12393677
Appl Microbiol Biotechnol. 2021 Feb;105(3):923-935
pubmed: 33427935
Brain Sci. 2021 Feb 10;11(2):
pubmed: 33578866
Fluids Barriers CNS. 2023 Jun 5;20(1):40
pubmed: 37277809
Alzheimers Dement. 2011 Sep;7(5):509-13
pubmed: 21723206
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Eur J Neurol. 2013 Feb;20(2):236-42
pubmed: 22672777
J Neuropathol Exp Neurol. 2009 Mar;68(3):227-40
pubmed: 19225413
Acta Neurochir (Wien). 2017 Dec;159(12):2293-2300
pubmed: 28889317
J Coll Physicians Surg Pak. 2019 Mar;29(3):218-221
pubmed: 30823945
Proc Natl Acad Sci U S A. 1990 Jul;87(13):5134-8
pubmed: 1695010
J Biol Chem. 1991 May 25;266(15):9912-8
pubmed: 2033076
Brain Commun. 2023 Jan 20;5(1):fcad011
pubmed: 36756308
Neurosurgery. 2005 Sep;57(3 Suppl):S4-16; discussion ii-v
pubmed: 16160425
Prog Neurobiol. 2022 Jul;214:102270
pubmed: 35447272
Geroscience. 2020 Oct;42(5):1323-1334
pubmed: 32458283
Brain Behav Immun Health. 2021 Oct 22;18:100370
pubmed: 34755124
J Alzheimers Dis. 2021;81(2):629-640
pubmed: 33814444
Fluids Barriers CNS. 2021 Dec 4;18(1):54
pubmed: 34863228
Immun Ageing. 2013 Feb 21;10(1):6
pubmed: 23432970
Braz J Med Biol Res. 2005 Sep;38(9):1359-65
pubmed: 16138219
J Virol Methods. 2010 Jan;163(1):116-22
pubmed: 19751768